Rybelsus is Novo Nordisk’s tablet form of semaglutide, approved for type 2 diabetes. It is the same molecule as Ozempic and Wegovy, taken by mouth rather than injected. It is FDA-approved — Tier A for that use.
Do not confuse it with oral Wegovy, a separate tablet approved for weight management in late 2025. Same molecule again; different label and different price.
Cash payers are worse off here. Rybelsus sits outside the flat-rate self-pay pricing Novo offers on Wegovy and Ozempic, so the discount routes that make those two affordable do not apply in the same way. Compare the routes in the cost calculator — and see cash price.